Hirsch 1982.

Study characteristics
Methods	Double‐blind placebo‐controlled RCT. Participants were individually assigned to either 30‐60mg/day of mianserin, 75‐150mg/day of nomifensine, or placebo (no further information on placebo provided). Follow‐up period: 12 weeks. N lost to follow‐up: 0/114 (0%) for repetition of SH.
Participants	Number of total participants: 114 participants, 38 were allocated to the mianserin arm, 38 were allocated to the nomifensine arm, and 38 to the placebo arm. Profile of participants: not stated. Source of participants: patients admitted to hospital following an episode of intentional drug overdose. Inclusion criteria: i) General Health Questionnaire (GHQ) score of over 20. Exclusion criteria: i) currently receiving antidepressant or antipsychotic medication.
Interventions	Intervention: oral administration of either 30 mg/day tp 60 mg/day of mianserin or 75 mg/day t 150 mg/ day of nomifensine. Control: placebo. No further information provided. Concomitant medication(s): no information on whether concomitant medication(s) were permitted was provided. Length of treatment: six weeks. Location: London, UK.
Outcomes	Primary outcome(s): i) repetition of SH (unclear how ascertained). Secondary outcome(s): i) depression, as measured by the HDRS, ii) adverse events, as measured by the Symptoms Emergent Checklist; iii) life events, as measured by the Brief Life Events Scale; iv) general health, as measured by the GHQ; v) treatment adherence, as measured by pill counts; vi) suicide (unclear how ascertained).
Notes	Funding: no details on funding provided. Conflict(s) of interest: no details on conflicts of interest provided. Other: data on depression and treatment adherence had to be excluded due to an inability to collect unpublished data from the trial authors for these outcomes.